Know Cancer

forgot password

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Phase 3
Not Enrolling
Peripheral T-Cell Lymphoma

Thank you

Trial Information

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Inclusion Criteria


Subjects must meet all of the following criteria to be included in the study:

1. Local pathologic diagnosis of PTCL with the following histology types: PTCL, not
otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and
anaplastic large cell lymphoma (ALCL) (ALK-negative or ALKpositive with IPI ≥ 2).

2. Stage II, III or IV disease.

3. Tumor lesion(s) measurable in 2 dimensions by computed tomography (CT) and is at
least 20 mm in the longest transverse dimension for non-lymph node masses and at
least 20 mm in longest transverse dimension for lymph nodes. Subcutaneous masses can
be used as indicator lesions. If the lesion was previously irradiated, it must have
progressed prior to randomization (by investigator assessment) to be used as a
measurable lesion.

4. Tumor biopsy available for central pathologic review; may be archived sample from
prior biopsy within 6 months of study enrollment, or sample to be obtained on study
during screening.

5. Age ≥ 18 years.

6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

7. Adequate bone marrow reserve as evidenced by:

- absolute neutrophil count (ANC) ≥ 1000/mm3 (1.0x109/L)

- platelets ≥ 50,000/mm3 (50x109/L); (≥ 25,000/mm3 [25x109/L] allowed if
thrombocytopenia secondary to bone marrow involvement by lymphoma)

- hemoglobin ≥ 8 g/dL (80 g/L)

8. Adequate liver function as evidenced by:

- bilirubin ≤ 1.5 times the upper limit of normal (ULN)

- aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT
[SGPT]) ≤ 3 times the ULN (≤ 5 times the ULN if hepatic involvement)

- albumin ≥ 3.0 g/dL (30 g/L)

9. Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL (176 μmol/L) or
calculated creatinine clearance ≥ 40 mL/min per the Cockcroft-Gault formula.

10. Willing and able to comply with all aspects of the protocol.

11. Written informed consent prior to any study-specific screening procedures.

12. Female subjects of childbearing potential must have a negative serum betahuman
chorionic gonadotropin (β-hCG) pregnancy test at Screening and a negative serum or
urine β-hCG pregnancy test result at Baseline, and must agree to use a highly
effective method of contraception (see protocol for list) throughout the entire study
period and for 30 days after study drug discontinuation.

13. Male subjects who are partners of women of childbearing potential must use or their
partners must use a highly effective method of contraception (see protocol for list)
beginning at least 1 menstrual cycle prior to starting study drug(s),throughout the
entire study period, and for 30 days after study drug discontinuation, unless they
are sexually abstinent or have undergone a successful vasectomy. Those with partners
using hormonal contraceptives must also be using an additional approved method of
contraception, as described previously.


Subjects who meet any of the following criteria will be excluded from the study:

1. Diagnosis of ALCL ALK-positive with IPI 0 or 1, adult T-cell leukemia/lymphoma
(ATLL), precursor T-cell lymphoblastic lymphoma/leukemia, extranodal NK/TCL nasal
type, enteropathy-associated TCL, hepatosplenic TCL, subcutaneous panniculitis-like
TCL, and cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary

2. Known central nervous system (CNS) involvement with lymphoma.

3. Prior chemotherapy, immunotherapy, denileukin diftitox, or investigational agent(s)
for this lymphoma, with the exception that a single cycle of CHOP (or CHOP-based
therapy) is allowed if the last dose of CHOP (or CHOP-based therapy) was administered
≤ 28 days before study enrollment (Lead-In) or randomization (Main Study).

4. Prior radiotherapy for this lymphoma, with the following exception: prior radiation
therapy for localized disease ≥ 4 weeks before randomization is allowed as long as
the irradiated area is not at the mediastinal area or at the site of the only
potentially measurable disease.

5. Prior malignancy within past 5 years (except non-melanoma skin cancer or carcinoma in
situ of the cervix).

6. Serious intercurrent illness.

7. Significant cardiac disease requiring ongoing treatment, including congestive heart
failure (CHF), severe coronary artery disease (CAD), cardiomyopathy, uncontrolled
cardiac arrhythmia, unstable angina pectoris, or myocardial infarction (MI) (within 6
months of study enrollment).

8. Left ventricular ejection fraction (LVEF) less than institutional lower limit of
normal, as determined by multigated acquisition scan (MUGA) or echocardiogram.

9. Major surgery within 2 weeks of study enrollment.

10. Active infections requiring specific anti-infective therapy.

11. Known human immunodeficiency virus (HIV) infection; known active hepatitis B or
hepatitis C infection.

12. Deep vein thrombosis within 3 months of study enrollment.

13. Females who are pregnant (positive urine test) or breastfeeding.

14. Any history of or concomitant medical condition that, in the opinion of the
Investigator, would compromise the subject's ability to safely complete the study.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate whether treatment of E7777 in combination with CHOP chemotherapy has superior efficacy compared with CHOP alone in improving progression-free survival (PFS) in first line treatment of subjects with peripheral T-cell lymphoma

Outcome Description:

Pretreatment or pre-randomization (screening and baseline): 4 weeks. Treatment: 18 weeks. Follow up: 2 to 3 years after the end of study treatment. Treatment will stop upon disease progression, unacceptable toxicity, or death, whichever occurs first. The Investigator or subject may also stop study treatment at any time for safety or personal reasons; however subject should remain on study, if possible, for follow-up.

Outcome Time Frame:

pre-randomization 4 weeks until disease progression

Safety Issue:


Principal Investigator

Chean Eng Ooi

Investigator Role:

Study Director

Investigator Affiliation:

Eisai Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

March 2011

Completion Date:

Related Keywords:

  • Peripheral T-cell Lymphoma
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral



Hinsdale, Illinois  60521
Hackensack, New Jersey  07601